gip and glp-1 receptor agonist Potential Use of GIP/GLP-1 Agonists for Respiratory Disorders: Where Are We at? Science Behind GLP 1 GIP

In this context, GLP-1 RA treatment has been shown to reduce diastolic filling pressures and other measures of diastolic performance (Saponaro et al., 2016

J Clin Res Pediatr Endocrinol

Both Ozempic, made by Novo Nordisk, and Mounjaro, made by Eli Lilly, are FDA-approved to treat Type 2 diabetes, but some doctors prescribe the medication "off-label" for weight loss, as is permissible by the FDA

intervention (Glucagon Like Peptide 1 RAs including: (Semaglutide, liraglutide, exenatide, or tirzepatide), alongside standard therapy)

32 A recent systematic review and meta-analysis supporting these findings also showed that GLP-1 RA use was not associated with cholecystitis or gallstones in overweight/obese individuals without diabetes